Effect of defibrination on tumor growth and response to chemotherapy.
Other investigators have demonstrated fibrin deposition in tumors. Experiments were therefore designed to test whether systemic defibrination would alter tumor growth or tumor response to chemotherapy with cyclophosphamide. Defibrination with Ancrod, a venom extract of Agkistrodon rhodostoma, did not significantly affect tumor sensitivity to chemotherapy. Similarly, defibrination plus fibrinolytic therapy with streptokinase did not affect responsiveness to cyclophosphamide. Long-term defibrination did not affect tumor growth. These results suggest three possible interpretations: (a) the coagulation system may not be important in tumor growth and response to chemotherapy; (b) adequate clearing of fibrin from the tumor was not accomplished in our experiments; or (c) other factors such as platelet deposition may be involved and platelet function was not inhibited by the therapies used in our experiments.
D000721:Ancrod / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001777:Blood Coagulation; D003520:Cyclophosphamide / Q000627:therapeutic use*; D010450:Endopeptidases / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000097:blood / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use
D003520:Cyclophosphamide; D010450:Endopeptidases; D013300:Streptokinase; D000721:Ancrod